Opinion: Even in a virtual JPM week, we need to maintain the relationship glue that keeps the biotech industry strong
Every January, the week of the annual J.P. Morgan Healthcare Conference (JPM week) is a whirlwind — oftentimes in the literal sense, with players from across the life science industry dodging the downpour in Union Square as we splash our way to back-to-back meetings.
Who would have thought that a year ago, when we were having the usual conversations about the expense of attending and whether it is worth it, that these issues would be solved for us: JPM week went virtual, following suit with the other conferences since Covid-19 was declared a global pandemic.
